Law360, New York (June 21, 2012, 7:39 PM ET) -- Bristol-Myers Squibb Co. on Thursday filed suit in Delaware federal court alleging Sandoz Inc.'s plan to make a generic version of the hepatitis B drug Baraclude would lead to infringement of BMS' patent for the medication.
BMS said in its complaint that unless Sandoz is blocked from carrying through with plans to make entecavir — the active ingredient in Baraclude — which it submitted in an abbreviated new drug application to the U.S. Food and Drug Administration, the generic maker would infringe BMS’s U.S. Patent Number...
Bristol-Myers Hits Sandoz Over Generic Hepatitis Drug
To view the full article, take a free trial now.
